A prospective assessment of renal transplantation versus haemodialysis: which therapeutic modality is good value for society?
Autor(a) principal: | |
---|---|
Data de Publicação: | 2014 |
Outros Autores: | , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | http://scielo.pt/scielo.php?script=sci_arttext&pid=S0872-01692014000400005 |
Resumo: | Background: Economic evaluations help health authorities facing budget constraints. This study compares the health-related quality of life (HRQOL) and costs in patient subgroups on haemodialysis (HD) and renal transplantation (KT). Methods: In a prospective study with follow-up of 1-3 years, we performed a costutility analysis of KT vs. HD, adopting a lifetime horizon. A societal perspective was taken. Costs for organ procurement, KT eligibility, transplant surgery and follow-up of living donors were included. Key clinical events were recorded. HRQOL was assessed using the EuroQol instrument. Results: The HRQOL remained stable on HD patients. After KT, mean utility score improved at 3 months while mean EQ-VAS scores showed a sustained improvement. Mean annual cost for HD was 32,567.57. Mean annual costs for KT in the year-1 and in subsequent years were, 60,210.09 and 12,956.77 respectively. Cost for initial hospitalization averaged 18,740.74. HLA-mismatches increased costs by 75% for initial hospitalization (p < 0.001) and 41% in the year-1 (p < 0.05), and duplicate the risk of readmission in the year-1 (p < 0.05). The incremental costutility ratio was 5,534.46/QALY, increasing 35% when costs for organ procurement were added. KT costs were 41,541.63 more but provided additional 7.51 QALY. Conclusions: The KT is cost-effective compared with HD. Public funding should reflect the value created by the intervention and adapt to the organ demand. |
id |
RCAP_a2c2c0eb32056acc357c2779b5cac404 |
---|---|
oai_identifier_str |
oai:scielo:S0872-01692014000400005 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
A prospective assessment of renal transplantation versus haemodialysis: which therapeutic modality is good value for society?Economic evaluationhaemodialysispublic fundingQALYquality-adjusted life yearsrenal transplantationBackground: Economic evaluations help health authorities facing budget constraints. This study compares the health-related quality of life (HRQOL) and costs in patient subgroups on haemodialysis (HD) and renal transplantation (KT). Methods: In a prospective study with follow-up of 1-3 years, we performed a costutility analysis of KT vs. HD, adopting a lifetime horizon. A societal perspective was taken. Costs for organ procurement, KT eligibility, transplant surgery and follow-up of living donors were included. Key clinical events were recorded. HRQOL was assessed using the EuroQol instrument. Results: The HRQOL remained stable on HD patients. After KT, mean utility score improved at 3 months while mean EQ-VAS scores showed a sustained improvement. Mean annual cost for HD was 32,567.57. Mean annual costs for KT in the year-1 and in subsequent years were, 60,210.09 and 12,956.77 respectively. Cost for initial hospitalization averaged 18,740.74. HLA-mismatches increased costs by 75% for initial hospitalization (p < 0.001) and 41% in the year-1 (p < 0.05), and duplicate the risk of readmission in the year-1 (p < 0.05). The incremental costutility ratio was 5,534.46/QALY, increasing 35% when costs for organ procurement were added. KT costs were 41,541.63 more but provided additional 7.51 QALY. Conclusions: The KT is cost-effective compared with HD. Public funding should reflect the value created by the intervention and adapt to the organ demand.Sociedade Portuguesa de Nefrologia2014-12-01info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articletext/htmlhttp://scielo.pt/scielo.php?script=sci_arttext&pid=S0872-01692014000400005Portuguese Journal of Nephrology & Hypertension v.28 n.4 2014reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPenghttp://scielo.pt/scielo.php?script=sci_arttext&pid=S0872-01692014000400005Domingos,MargaridaGouveia,MiguelPereira,JoãoNolasco,Fernandoinfo:eu-repo/semantics/openAccess2024-02-06T17:04:46Zoai:scielo:S0872-01692014000400005Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-20T02:18:53.333746Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
A prospective assessment of renal transplantation versus haemodialysis: which therapeutic modality is good value for society? |
title |
A prospective assessment of renal transplantation versus haemodialysis: which therapeutic modality is good value for society? |
spellingShingle |
A prospective assessment of renal transplantation versus haemodialysis: which therapeutic modality is good value for society? Domingos,Margarida Economic evaluation haemodialysis public funding QALY quality-adjusted life years renal transplantation |
title_short |
A prospective assessment of renal transplantation versus haemodialysis: which therapeutic modality is good value for society? |
title_full |
A prospective assessment of renal transplantation versus haemodialysis: which therapeutic modality is good value for society? |
title_fullStr |
A prospective assessment of renal transplantation versus haemodialysis: which therapeutic modality is good value for society? |
title_full_unstemmed |
A prospective assessment of renal transplantation versus haemodialysis: which therapeutic modality is good value for society? |
title_sort |
A prospective assessment of renal transplantation versus haemodialysis: which therapeutic modality is good value for society? |
author |
Domingos,Margarida |
author_facet |
Domingos,Margarida Gouveia,Miguel Pereira,João Nolasco,Fernando |
author_role |
author |
author2 |
Gouveia,Miguel Pereira,João Nolasco,Fernando |
author2_role |
author author author |
dc.contributor.author.fl_str_mv |
Domingos,Margarida Gouveia,Miguel Pereira,João Nolasco,Fernando |
dc.subject.por.fl_str_mv |
Economic evaluation haemodialysis public funding QALY quality-adjusted life years renal transplantation |
topic |
Economic evaluation haemodialysis public funding QALY quality-adjusted life years renal transplantation |
description |
Background: Economic evaluations help health authorities facing budget constraints. This study compares the health-related quality of life (HRQOL) and costs in patient subgroups on haemodialysis (HD) and renal transplantation (KT). Methods: In a prospective study with follow-up of 1-3 years, we performed a costutility analysis of KT vs. HD, adopting a lifetime horizon. A societal perspective was taken. Costs for organ procurement, KT eligibility, transplant surgery and follow-up of living donors were included. Key clinical events were recorded. HRQOL was assessed using the EuroQol instrument. Results: The HRQOL remained stable on HD patients. After KT, mean utility score improved at 3 months while mean EQ-VAS scores showed a sustained improvement. Mean annual cost for HD was 32,567.57. Mean annual costs for KT in the year-1 and in subsequent years were, 60,210.09 and 12,956.77 respectively. Cost for initial hospitalization averaged 18,740.74. HLA-mismatches increased costs by 75% for initial hospitalization (p < 0.001) and 41% in the year-1 (p < 0.05), and duplicate the risk of readmission in the year-1 (p < 0.05). The incremental costutility ratio was 5,534.46/QALY, increasing 35% when costs for organ procurement were added. KT costs were 41,541.63 more but provided additional 7.51 QALY. Conclusions: The KT is cost-effective compared with HD. Public funding should reflect the value created by the intervention and adapt to the organ demand. |
publishDate |
2014 |
dc.date.none.fl_str_mv |
2014-12-01 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://scielo.pt/scielo.php?script=sci_arttext&pid=S0872-01692014000400005 |
url |
http://scielo.pt/scielo.php?script=sci_arttext&pid=S0872-01692014000400005 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
http://scielo.pt/scielo.php?script=sci_arttext&pid=S0872-01692014000400005 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Sociedade Portuguesa de Nefrologia |
publisher.none.fl_str_mv |
Sociedade Portuguesa de Nefrologia |
dc.source.none.fl_str_mv |
Portuguese Journal of Nephrology & Hypertension v.28 n.4 2014 reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799137279054184448 |